KORU Medical Systems, Inc.(KRMD)Stock Analysis
AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →13F Pro Quality Score
Rank #2,106 of 2,962 stocks
Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Nov 14, 2026.
Revenue Growth
Profitability
Balance Sheet
Earnings Quality
Free Cash Flow
Institutional Flow
Revenue Scale
Dilution Risk
KRMD Stock Analysis & AI Quality Score
Data updated 2026-09-11AI stock analysis and institutional research for KORU Medical Systems, Inc. (KRMD), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores KRMD at 40.4/100 on a 32-signal composite quality model, placing it at rank #2,106 of 2,962 stocks — the bottom half of the AI-ranked universe. KRMD scores in the top quartile across revenue growth (81.4). Areas of concern include revenue scale (8.0) and balance sheet strength (20.2), which score below median versus the broader universe. Shareholder dilution risk is elevated at 21.2/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q2 2026), KORU Medical Systems, Inc. reports quarterly revenue of $12.0M, net income of $252.4K, free cash flow of $108.2K. Top institutional holders of KRMD by reported 13-F value include First Light Asset Management, Topline Capital Management, BlackRock, based on the most recent SEC filings. KRMD trades on the Nasdaq exchange and files with the SEC under CIK 704440. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate KRMD daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for KORU Medical Systems, Inc. directly from SEC EDGAR. KORU Medical Systems, Inc.'s 13F Pro composite quality score has ranged between 14 and 40 since 2023, currently 40.4 — an improving long-term trajectory across 60 quarterly and live scoring snapshots.
Revenue
Q2 2026
$12.0M
Net Income
Q2 2026
$252.4K
Free Cash Flow
Q2 2026
$108.2K
ROIC
Q2 2026
13.9%
Revenue & Net Income
Earnings Per Share
Key Financials Over Time
Export Financial Table · ProRevenue
+22.2% YoYNet Income
+56.5% YoYOperating Income
+53.9% YoYEPS (Diluted)
+53.8% YoYTotal Assets
+3.6% YoYOp. Cash Flow
+244.6% YoYFree Cash Flow
+70.9% YoY| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Revenue | $41.1M +22.2% | $33.6M +18.0% | $28.5M +2.2% | $27.9M +18.8% | $23.5M -2.8% | $24.2M |
| Net Income | $-2.6M +56.5% | $-6.1M +55.9% | $-13.7M -58.7% | $-8.7M -89.8% | $-4.6M -276.5% | $-1.2M |
| Operating Income | $-3.0M +53.9% | $-6.4M +37.2% | $-10.3M +4.7% | $-10.8M -53.4% | $-7.0M -460.2% | $-1.3M |
| EPS (Diluted) | $-0.06 +53.8% | $-0.13 +56.7% | $-0.30 -57.9% | $-0.19 -90.0% | $-0.10 -233.3% | $-0.03 |
| Total Assets | $28.2M +3.6% | $27.2M -4.4% | $28.5M -32.8% | $42.3M +2.5% | $41.3M +3.4% | $39.9M |
| Operating Cash Flow | $462.4K +244.6% | $-319.7K +93.5% | $-4.9M +9.5% | $-5.4M -25.1% | $-4.3M -481.1% | $-743.3K |
| Free Cash Flow | $-470.1K +70.9% | $-1.6M +71.5% | $-5.7M +30.5% | $-8.2M -75.0% | $-4.7M -180.4% | $-1.7M |
Get alerted when KRMD's score changes
Free account: watchlist tracking, the daily AI brief, and the AI screener.
Available Research
13F Pro tracks comprehensive data for KORU Medical Systems, Inc. including:
Top Institutional Holders of KRMD
First Light Asset Management, LLC
$14.2M3,387,902 shTopline Capital Management, LLC
$14.2M3,373,842 shBlackRock, Inc.
$11.0M2,628,352 shVANGUARD CAPITAL MANAGEMENT LLC
$7.6M1,818,121 shGEODE CAPITAL MANAGEMENT, LLC
$4.7M1,128,096 shSimcoe Capital LLC
$3.5M827,393 shMeros Investment Management, LP
$3.2M759,664 shLionhunter Capital Management, LLC
$2.9M693,139 shSTATE STREET CORP
$2.7M646,572 shArchon Capital Management LLC
$2.7M642,923 sh
| Fund | Value | Shares |
|---|---|---|
| First Light Asset Management, LLC | $14.2M | 3,387,902 |
| Topline Capital Management, LLC | $14.2M | 3,373,842 |
| BlackRock, Inc. | $11.0M | 2,628,352 |
| VANGUARD CAPITAL MANAGEMENT LLC | $7.6M | 1,818,121 |
| GEODE CAPITAL MANAGEMENT, LLC | $4.7M | 1,128,096 |
| Simcoe Capital LLC | $3.5M | 827,393 |
| Meros Investment Management, LP | $3.2M | 759,664 |
| Lionhunter Capital Management, LLC | $2.9M | 693,139 |
| STATE STREET CORP | $2.7M | 646,572 |
| Archon Capital Management LLC | $2.7M | 642,923 |
Companies Similar to KRMD
Ranked by quality-profile closeness and shared hedge-fund ownership — not just sector membership.
TriSalus Life Sciences, Inc.
NeuroPace Inc
Cryoport, Inc.
Apyx Medical Corp
AtriCure, Inc.
ESTABLISHMENT LABS HOLDINGS INC.
Similarity is computed from the 8 composite sub-scores and latest-quarter 13F conviction holdings (index-style filers excluded). Refreshed monthly.
More Healthcare Companies
View all Healthcare →Put KRMD on your watchlist
Track score changes the day KORU Medical Systems, Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.
Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).
Popular Research
Is KRMD a good stock to buy?
13F Pro's AI-powered analysis of KORU Medical Systems, Inc. (KRMD) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for KRMD are available on the KRMD stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing. KRMD is classified as a small company.
Which hedge funds own KRMD?
Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling KRMD. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of KORU Medical Systems, Inc.'s investment landscape.